Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Subscribe To Our Newsletter & Stay Updated